Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study

Massimo Volpe, Peter Brommer, Uwe Haag, Cristina Miele

Research output: Contribution to journalArticlepeer-review

Abstract

Background and objectives: Cerebrovascular and cardiac adverse events can be significantly reduced by effective antihypertensive therapy; however, BP control rates remain poor. The objective of this randomized, double-blind, parallel-group, multicentre study was to determine the efficacy and safety of olmesartan medoxomil/amlodipine combination therapy in patients with moderate to severe hypertension who had failed to respond to treatment with 8 weeks of open-label amlodipine. Methods: A total of 1017 patients entered the open-label amlodipine monotherapy stage; mean BP at week 0 was 164/102 mmHg. After 8 weeks of amlodipine monotherapy (5 mg/day), non-responding patients (n = 755) were randomized to receive placebo plus amlodipine 5 mg or a combination of olmesartan medoxomil (10-40 mg) with amlodipine 5 mg for 8 weeks. At week 16, patients who had achieved diastolic BP (DBP)

Original languageEnglish
Pages (from-to)11-25
Number of pages15
JournalClinical Drug Investigation
Volume29
Issue number1
DOIs
Publication statusPublished - 2009

Keywords

  • Amlodipine, therapeutic use
  • Angiotensin II 1 receptor antagonists, therapeutic use
  • Antihypertensives, therapeutic use
  • Calcium channel agonists, therapeutic use
  • Hypertension
  • Olmesartan medoxomil, therapeutic use

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study'. Together they form a unique fingerprint.

Cite this